Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation.


Journal Article

A new research study evaluated the mechanisms of prostate cancer (PCa) resistance to androgen deprivation therapy (ADT) and progression to castrate-resistant disease. Using a coclinical approach, the investigators were able to identify key genetic determinants of ADT resistance, gain insight into the molecular pathways that play a key role in this transition and propose a potential management strategy to overcome ADT resistance in select cancers. This represents a step forward towards personalized medicine guided by specific molecular markers of prostate cancer enabling more effective therapies targeted towards altered metabolic pathways.

Full Text

Cited Authors

  • Stanevsky, Y; Tsivian, A; Tsivian, M

Published Date

  • November 2013

Published In

Volume / Issue

  • 15 / 6

Start / End Page

  • 709 - 710

PubMed ID

  • 23893155

Pubmed Central ID

  • 23893155

Electronic International Standard Serial Number (EISSN)

  • 1745-7262

Digital Object Identifier (DOI)

  • 10.1038/aja.2013.96


  • eng

Conference Location

  • China